Month: March 2023

National Hunt Sales Catalogues to Reference Point to Point Wins

There has been a change to the treatment of point-to-point performances in sale company catalogues, the International Cataloguing Standards Committee (ICSC) European sub-committee announced on Friday.

Currently, winning British and Irish point-to-point performers are classified as runners, but not as winners in either the subject horse detail or the dam summary line. For all National Hunt sales from April 2023 onwards, if the progeny of a dam has won a point-to-point in Great Britain or Ireland but the same animal has not won under rules the point-to-point only, winner(s) will be referenced as point-to-point only winners in the dam summary line and/or produce summary.

Progeny that have won both under rules races and in a point to point will continue to be described as a winner as currently. Sale catalogues which are designated 'Flat' will continue to not treat winning point-to-point performances as wins and not reference any progeny which were point to point winners only.

Tattersalls Ireland's Simon Kerins and Nick Nugent of Goffs jointly said, “This rule change gives greater clarity around the presentation of form in National Hunt catalogues. It addresses the clear anomaly whereby catalogues have listed any point-to-point performers to be runners for the dam, but do not consider a winner of such a contest to be relevant for the mare.”

The post National Hunt Sales Catalogues to Reference Point to Point Wins appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Quality Road’s Cairo Back With A Bang At Dundalk

Coolmore and Westerberg's 3-year-old colt Cairo (Ire) (Quality Road–Cuff {Ire}, by Galileo {Ire}), a multiple Classic entry, justified long odds-on favouritism with a comfortable success in Friday's one-mile Listed Patton S. at Dundalk. The homebred bay followed up an August maiden win at the Curragh with a second in the Co. Louth venue's Sept. 30 Listed Star Appeal S. and closed his juvenile campaign with a 2 3/4-length triumph in October's G3 Killavullan S. at Leopardstown. The eventual winner, Aidan O'Brien's first domestic runner of the year, was sharply into stride from the outside stall and raced in a close-up second through halfway. Nudged along to gain control soon after turning for home, the 3-10 chalk was not for catching thereafter and kept on strongly under urging inside the final furlong to prevail by two lengths from News At Ten (GB) (Twilight Son {GB}).

Cairo is the third of five foals and one of two winners from as many runners produced by Listed Naas Fillies' Sprint S. victrix Cuff (Ire) (Galileo {Ire}), herself kin to six black-type performers headed by MG1SP sire Gustav Klimt (Ire) (Galileo {Ire}), G1 Gran Criterium heroine Nayarra (Ire) (Cape Cross {Ire}) and G1 St James's Palace S. third Mars (Ire) (Galileo {Ire}). The April-foaled bay's second dam, MGSP Listed Empress S. victrix Massarra (GB) (Danehill), is daughter of G1 Prix de Diane heroine Rafha (GB) (Kris {GB}) and thus a half-sister to G1 Haydock Sprint Cup-winning sire Invincible Spirit (Ire) (Green Desert) and to the dam of three-time Group 1 winner Mishriff (Ire) (Make Believe {GB}). He is half to a 2-year-old filly by No Nay Never and a yearling colt Wootton Bassett (GB).

 

The post Quality Road’s Cairo Back With A Bang At Dundalk appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Two Entries Added To Fasig-Tipton March Digital Sale

Fasig-Tipton has added a pair of offerings to its March Digital Sale, which is now open for bidding. Bidding closes Tuesday, March 7, beginning at 2 p.m. ET.

The new entries include:

– Mount Craig (Hip 11): Four-year-old racing/stallion prospect by Arrogate, who placed in maiden special weight company at Oaklawn Park on March 2. Mount Craig hails from the immediate family of Eclipse Champion Good Magic.

– Cajun Kid (Hip 42): Five-year-old broodmare prospect by Lemon Drop Kid from the immediate family of Grade 1 winners Union Rags and Declaration of War.

The full catalog features horses of racing age, breeding stock, 2-year-olds, and yearlings.

The post Two Entries Added To Fasig-Tipton March Digital Sale appeared first on Horse Racing News | Paulick Report.

Source of original post

Biologic Therapies For Management Of Equine Arthritis: What Are They, And How Do They Work?

In the last few years, a plethora of regenerative therapy options for horses suffering from osteoarthritis have come onto the market. Regenerative therapies focus on depositing new tissue with similar biomechanical function to the original tissue. It differs from tissue reparation, which involves scar tissue, explained Dr. Gustavo M. Zanotto, clinical associate professor of equine sports medicine at Texas A&M University's School of Veterinary Medicine and Biomedical Sciences.

Limiting inflammation and scar tissue formation makes tissue more functional, reports The Horse. Many vets are now using biologic therapies in the joint, preferring them over corticosteroid joint injections for longer-term efficacy, though there are no studies regarding long-term benefit.

Regenerative medicine involves two proteins: interlekin-1 receptor antagonist protein (IRAP) and growth factors. IRAP is often used in joints; it blocks the cytokine's destructive effects on cartilage. Growth factors stimulate cell growth and survival, tissue repair, inflammation reduction, and cell differentiation.  

The use of autologous conditioned serum (ACS) involves collecting blood from the affected horse and incubating it with borosilicate glass beads, which stimulate the white blood cells to release anti-inflammatory cytokines. This is then injected back into the affected joint, stimulating the body to produce more IRAP. The affected joint becomes less painful and the product slows cartilage breakdown. 

ACS can also be used to improve healing in tendon injuries.

Platelet-rich plasma (PRP) is often used for equine tendon injuries. To get PRP, the vet collects blood from the affected horse, combines it with an anticoagulant and separates the cells into platelets and red and white blood cells. These are then injected into the affected tendon. PRP can also be used in joints affected by osteoarthritis (OA).

Autologous protein solution (APS) is derived from plasma and can also be used for horses with OA. It has shown to improve lameness in a small study. 

Alpha-2 macroglobulin products (A2M) are used in joints; coagulants are added to blood drawn from an affected horse, put in a centrifuge and the platelet-poor plasma is injected into a concentration kit. The concentrated A2M plasma is then injected back into the horse. It's believed that this limits the breakdown of cartilage by trapping the metalloproteinases.

Zanotto emphasized that not every horse will heal the same way, no matter what biologic product is used, and that no one modality will work for every horse. He reminded vets that they cannot control the variance in horse's blood or the products derived from them. 

Read more at The Horse.

The post Biologic Therapies For Management Of Equine Arthritis: What Are They, And How Do They Work? appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights